-
TYK Medicines Inc.’s TY-9591 Shows Superiority Over Osimertinib in EGFR Mutated Lung Cancer with Brain Metastasis
•
Zhejiang-based TYK Medicines Inc. (HKG: 2410) announced positive results from a pivotal Phase II study positioning TY-9591 against osimertinib as a first-line treatment for epidermal growth factor receptor (EGFR) mutated lung cancer with brain metastasis. The data demonstrated statistical significance and significant clinical benefits, marking a potential breakthrough in the…
-
TYK Medicines Files for IPO on HKSE Amid Rising Losses and Expanding Drug Pipeline
•
Zhejiang-based TYK Medicines Inc. (HKG: 2410) has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange (HKSE). The company reported revenues of RMB 44 million and a loss of RMB 312 million in 2022, primarily generated through a licensing agreement with Livzon Pharma. In the first…
-
TYK Medicines Secures Nearly RMB 200 Million in Series D Financing Led by Sichuan Huiyu Pharmaceutical
•
Shanghai-based TYK Medicines (HKG: 2410) has successfully completed a Series D financing round, raising nearly RMB 200 million (approximately USD 28 million). The round was led by Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA: 688553), with additional investments from CICC Capital, Changxing Financial Holding, and the Huzhou Talent Fund. Founded in…
